- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04610931
Study of the Effectiveness of a Virtual Reality Treatment in the Management of Smoking Cessation (3DSmoke)
Study Overview
Status
Conditions
Detailed Description
Smoking is the leading cause of morbidity and mortality, making it one of the most serious public health problems in the world. The majority of smokers would like to stop smoking and the number of smokers seeking treatment has increased by 25% between 2017 and 2018 in France. Indeed, many effective interventions have been developed to stop smoking, but many patients continue to relapse after a quit attempt. Only 10% to 30% achieve long-term abstinence and the majority relapse.
The therapeutic approach to addiction is based on a bio-psycho-social model. It aims to limit the runaway of subcortical processes (the cause of craving) via a medicinal approach and to strengthen the cortical control mechanisms via a psychotherapeutic approach.
As far as psychotherapeutic approaches are concerned, they seek to obtain a modification of cognitions and emotions related to tobacco through, for example, a relearning of the management of the product mediated by evocation or exposure. This may involve, for example, the repeated presentation (or evocation) of a signal (e.g. a place of consumption...), previously linked to consumption but in the absence of a reinforcer (product consumption). Most addiction remediation therapies have been developed and practiced with "imagination" (the patient is asked to think of stimulating situations) but they are difficult to control (because the patient's imagination can be more or less large) and are rarely used with situations that induce consumption. In this context the use of a 3Dimension (3D) tool, which allows a controlled and progressive exposure without confrontation, seems an interesting perspective. Virtual reality is recognized as a "tool" in the fields of neuroscience and psychology. It allows a patient-controlled exposure to complex, dynamic and three-dimensional stimuli.
Thus, virtual reality has logically been proposed as a tool in exposure therapies and its benefit has been measured in substance dependencies (Hone-Blanchet et al 2014). Since 2000, several researchers have successfully used virtual reality applications in addictions, but there is little data on objective evaluations of the effectiveness of cybertherapy in the treatment of tobacco addiction, particularly in association with the two reference treatments for smoking cessation that are nicotine substitution associated with cognitive behavioural therapy. For tobacco, the results are heterogeneous and did not take into account the different factors for maintaining tobacco use (Lee et al 2004, Choi et al 2011, Park et al 2014). Virtual therapy appears to be more effective when combined with other relapse prevention techniques such as cognitive behavioural therapy (CBT).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lise Laclautre
- Phone Number: 0473754963
- Email: promo_interne_drci@chu-clermontferrand.fr
Study Locations
-
-
Auvergne
-
Clermont-Ferrand, Auvergne, France, 63000
- Recruiting
- Clermont-Ferrand University Hospital
-
Sub-Investigator:
- Aurore Tremey
-
Sub-Investigator:
- Morgane Rude-Bache
-
Sub-Investigator:
- Jean Perriot
-
Principal Investigator:
- Georges Brousse
-
Contact:
- Lise Laclautre
- Phone Number: 0473754963
- Email: promo_interne_drci@chu-clermontferrand.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female between 18 and 75 years of age
- Who smokes 10 or more cigarettes per day in the month prior to inclusion
- Who wants to quit smoking
- Who has a diagnosis of a smoking disorder with "craving" criteria according to DSM 5 criteria
- Who is able to speak and read French
- Who is covered by the French national health insurance system
- Who has a signed consent form
Exclusion Criteria:
- Subjects with decompensated psychiatric co-morbidities (DSM 5) or unstable organic disease
- Subjects at serious suicide risk
- Subjects with other substance use disorders (DSM 5)
- Problems that interact with 3D exposure: tendency to dissociation; interceptive phobias (panic attacks and hypochondria...); severe dizziness.
- Cognitive problems that limit or prevent the ability to implement coping strategies or the management of emotions or stimuli and disabilities to complete the questionnaires
- Subjects belonging to a protected population such as pregnant women, breastfeeding women, guardians
- Subjects deprived of liberty by judicial or administrative decision, subject to psychiatric treatment under duress, minor subject, or unable to express their consent
- Who refuses to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cybertherapy
use of cybertherapy (6 sessions) in addition to cognitive behavioral therapy (6 sessions) + pharmacological treatment
|
Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage. Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level. |
Active Comparator: Treatment as usual
Treatment as usual is a cognitive behavioral therapy (6 sessions) + pharmacological treatment
|
Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage. Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients who quit smoking
Time Frame: Day 43
|
Comparison of proportion of patients who quit smoking after 6 weeks after intervention in the 2 arms (declarative status verified by measurement of carbon monoxide level in the expired air) and until one year.
|
Day 43
|
Percentage of patients who quit smoking
Time Frame: Day 136
|
Comparison of proportion of patients who quit smoking after 6 weeks after intervention in the 2 arms (declarative status verified by measurement of carbon monoxide level in the expired air) and until one year.
|
Day 136
|
Percentage of patients who quit smoking
Time Frame: Day 229
|
Comparison of proportion of patients who quit smoking after 6 weeks after intervention in the 2 arms (declarative status verified by measurement of carbon monoxide level in the expired air) and until one year.
|
Day 229
|
Percentage of patients who quit smoking
Time Frame: Day 408
|
Comparison of proportion of patients who quit smoking after 6 weeks after intervention in the 2 arms (declarative status verified by measurement of carbon monoxide level in the expired air) and until one year.
|
Day 408
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
smoking decreasing
Time Frame: Day 229, Day 408
|
Comparison between arms of mean/median number of cigarette smoke per day (declarative status and measurement of carbon monoxide level in the expired air)
|
Day 229, Day 408
|
Craving score
Time Frame: Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
|
evaluation of craving score with Tabacco Craving Questionnary sort Form questionnaire (7 to 84; 7 no craving and 84 highest craving) ; comparison between arms at different endpoints
|
Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
|
Needing score
Time Frame: Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
|
It is evaluated with an analogical visual scale (1 to 10; 1 the lowest 10 the highest); comparison between arms at different endpoints
|
Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
|
e-health score
Time Frame: Day 1, Day 43
|
It is evaluated with disease simulation questionnaire (French Speach Spatial en Quality -SSQ-vf- questionnaire)(/16)
|
Day 1, Day 43
|
Follow-up of all virtual reality sessions
Time Frame: Day 43
|
Follow-up of all virtual reality sessions is assessed at 6 weeks post-inclusion
|
Day 43
|
Relapse rate
Time Frame: Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
|
Relapse rate is the percentage of participants who are abstinent at the end of treatment and who relapse during the follow-up period; comparison between arms at different endpoints
|
Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
|
Level of anxiety and depression
Time Frame: Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
|
It is evaluated with the Hospital Anxiety and Depression - HAD scale (1 to 21; 1 no anxiety and depression , 21 highest symptoms); comparison between arms at different endpoints
|
Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RBHP 2020 BROUSSE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use Cessation
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Vanderbilt University Medical CenterCompletedTobacco Use | Tobacco Use Cessation
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VirginiaVirginia Foundation for Healthy YouthRecruitingTobacco Use | Electronic Cigarette Use | Tobacco Use CessationUnited States
-
HealthPartners InstituteMinnesota Partnership for Action Against TobaccoCompleted
-
University of California, Los AngelesNYU Langone Health; Olive View-UCLA Education & Research InstituteEnrolling by invitationSmoking Cessation | Tobacco Use CessationUnited States
-
The University of Hong KongFood and Health Bureau, Hong KongCompletedSmoking Cessation | Tobacco Use CessationHong Kong
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedTobacco Use Cessation | Tobacco PreventionUnited States
-
The University of Hong KongQueen Elizabeth Hospital, Hong Kong; Food and Health Bureau, Hong Kong; Queen... and other collaboratorsCompletedSmoking Cessation | Tobacco Use CessationHong Kong
Clinical Trials on Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)
-
Hacettepe UniversityHacettepe University Scientific Research Projects Coordination Unit; THE SCIENTIFIC...RecruitingKinesiophobia | Re-injury Anxiety | Poor Rehabilitation Adherence | Poor Rehabilitation Self EfficacyTurkey
-
Tomorrow Sp. z o.o.National Center for Research and Development, PolandCompleted
-
King's College LondonGuy's and St Thomas' NHS Foundation Trust; National Institute for Health Research... and other collaboratorsUnknownAutism Spectrum Disorder | Social AnxietyUnited Kingdom
-
University Hospital, Clermont-FerrandFondation de l'Avenir, FranceUnknownAddiction | Cocaine-Related DisordersFrance
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Recruiting
-
Region of Southern DenmarkOdense University Hospital; University of Southern Denmark; Universite du Quebec... and other collaboratorsActive, not recruitingSocial Anxiety | Social PhobiaDenmark
-
Weill Medical College of Cornell UniversityCompletedPosttraumatic Stress Disorder | Substance AbuseUnited States
-
Universidad Nacional Autonoma de MexicoIstituto Auxologico Italiano; Medica Sur Clinic & FoundationUnknown
-
Vilnius UniversityLinkoeping University; Stockholm University; Thomas More University of Applied...Not yet recruiting
-
Weill Medical College of Cornell UniversityBrain & Behavior Research FoundationTerminatedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States